L’actualité de Novigenix
Suivez toute l’actualité de Novigenix
Novigenix receives ISO 13485 Certification from BSI
Geneva, September 11, 2024 - Novigenix, a leader in AI-driven healthcare solutions, successfully achieved ISO 13485:2016 certification, passing the Stage II audit with zero non-conformities. This milestone underscores Novigenix's unwavering commitment to the highest standards of quality in providing solutions for the biopharma industry. ISO 13485:2016 is an internationally recognized standard for quality management systems in the medical device industry.
Novigenix honored as Best 2024 Technology Innovation in oncology by MATWIN Board
Lausanne, May 29, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has been awarded the prestigious recognition of 'Best 2024 Technology Innovation' in oncology by the MATWIN Board, the premier European convention dedicated to innovation in cancer treatment. This recognition highlights Novigenix's groundbreaking contributions to personalized cancer care and its commitment to advancing oncology through cutting-edge technology. Brian
Revolutionizing Colorectal Cancer Screening with Novigenix Innovations
Recent research in the New England Journal of Medicine highlights significant advances in colorectal cancer (CRC) screening. Novigenix leads this innovation with our unique approach that combines liquid biopsy, AI, and RNA analysis, promising a transformative impact on early cancer detection. Colorectal cancer is a major global health concern, projected to rise by 63% by 2040. Despite current screening
Novigenix and IMMUcan forge a transformative partnership in AI-driven immunotherapy advancements
04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan consortium aims to advance cancer research
Revolutionizing drug development: Novigenix unveils AI-powered RNA analysis for immune response profiling
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as unique as the person it
Novigenix appoints Dr. Pedro Romero as Chief Medical & Scientific Officer
LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix. In his new role as Chief